Skip to main content
Clinical Trials/JPRN-UMIN000001485
JPRN-UMIN000001485
Completed
Phase 2

Allogeneic stem cell transplantation following reduced-intensity conditioning for relapsed/refractory peripheral T-cell non-Hodgkin's lymphomas - Allogeneic stem cell transplantation following reduced-intensity conditioning for relapsed/refractory peripheral T-cell non-Hodgkin's lymphomas

West Japan Hematology Oncology Group/ Hematological Malignancy Therapy Study Group/ Japan Study Group for Cell Therapy and Transplantation0 sites30 target enrollmentNovember 7, 2008

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
relapsed/refractory peripheral T-cell non-Hodgkin&#39
Sponsor
West Japan Hematology Oncology Group/ Hematological Malignancy Therapy Study Group/ Japan Study Group for Cell Therapy and Transplantation
Enrollment
30
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 7, 2008
End Date
September 1, 2017
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
West Japan Hematology Oncology Group/ Hematological Malignancy Therapy Study Group/ Japan Study Group for Cell Therapy and Transplantation

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Any of the following. A history of autologous transplantation just before enrolment, Positive for HLA antibody (in case of cord blood transplantation), SaO2 bellow 94% in room air, T.Bil over 2\.0 mg/dL, Serum creatinine over 2\.0 mg/dL, AST or ALT over 2\.5xULN, Uncontrolled diabetes, Uncontrolled hypertension, History of severe cardiac disease, Left ventricular ejection fraction smaller than 50%, Patients with other malignant comorbidity, Uncontrolled active infection, Positive for TPHA or HTLV\-1 antibody or HIV antibody or HBs antigen, Uncontrolled psychiatric disease, Allergic history to drugs used in the present conditioning regimen or GVHD prophylaxis regimen, Pregnant or during breast feeding, Cases that physicians judged as inappropriate,

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CChronic lymphocytic leukemiaMedDRA version: 14.1Level: LLTClassification code 10008978Term: Chronic lymphocytic leukemia refractorySystem Organ Class: 100000004864MedDRA version: 14.1Level: LLTClassification code 10008977Term: Chronic lymphocytic leukemia recurrentSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2007-005487-28-NLHOVON Foundation50
Completed
Phase 2
Allogeneic Stem Cell Transplantation after Reduced Intensity Conditioning for High-risk Relapsed or Refractory CB-CLL10024324
NL-OMON38321HOVO40
Completed
Phase 1
Allogeneic stem cell transplantation for relapsed/refractory aggressive lymphoma with conditioning regimen consisted of fludarabine, iv busulfan, and melphalan (single center prospective trial)
JPRN-UMIN000013940Department of Hematology Toranomon Hospital12
Active, not recruiting
Phase 1
Stem cells transplant from matched donor in patients with chronic myeloid leukemia who do not improve with TKI therapyChronic Myeloid LeukemiaMedDRA version: 18.0Level: LLTClassification code 10054352Term: Chronic phase chronic myeloid leukemiaSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]
EUCTR2014-003126-40-ITIVERSITà DEGLI STUDI MILANO BICOCCA20
Completed
Not Applicable
Allogeneic hematopoietic stem cell transplantation for elderly patients
JPRN-UMIN000017744nivesity of Tokyo Hospital, Department of Hematology and Oncology50